Cargando…

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis

Detalles Bibliográficos
Autores principales:	Zhan, Haoting, Yang, Li, Liu, Yongmei, Li, Haolong, Li, Xiaomeng, Wang, Haibin, Cao, Jinfeng, Kang, Shuhui, Guo, Xinru, Dai, Erhei, Li, Yongzhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867801/ https://www.ncbi.nlm.nih.gov/pubmed/36693568 http://dx.doi.org/10.1016/j.jinf.2023.01.030

Ejemplares similares

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases
por: Liu, Yongmei, et al.
Publicado: (2023)

SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China
por: Liu, Yongmei, et al.
Publicado: (2023)

The Roles of Noncoding RNAs in Systemic Sclerosis
por: Liu, Yongmei, et al.
Publicado: (2022)

Antibody response to inactivated COVID‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization
por: Li, Haolong, et al.
Publicado: (2023)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Alterations of m6A RNA methylation regulators contribute to autophagy and immune infiltration in primary Sjögren’s syndrome
por: Cheng, Linlin, et al.
Publicado: (2022)

Plasma lipidomics of primary biliary cholangitis and its comparison with Sjögren’s syndrome
por: Li, Haolong, et al.
Publicado: (2023)

Development and validation of diagnostic and activity-assessing models for relapsing polychondritis based on laboratory parameters
por: Liu, Yongmei, et al.
Publicado: (2023)

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis
por: Li, Xiaomeng, et al.
Publicado: (2022)

Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis
por: Zhan, Haoting, et al.
Publicado: (2021)

Novel Insights Into Gene Signatures and Their Correlation With Immune Infiltration of Peripheral Blood Mononuclear Cells in Behcet’s Disease
por: Zhan, Haoting, et al.
Publicado: (2021)

Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis
por: Chen, Si, et al.
Publicado: (2022)

Identification of novel genes in Behcet’s disease using integrated bioinformatic analysis
por: Chen, Si, et al.
Publicado: (2022)

Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression
por: Zhan, Haoting, et al.
Publicado: (2021)

COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China
por: Xu, Yali, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
por: Chen, Chen, et al.
Publicado: (2023)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Chemokines and chemokine receptors in Behçet’s disease
por: Li, Zhan, et al.
Publicado: (2023)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901
por: von Reyn, C. Fordham, et al.
Publicado: (2017)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Assessing the acceptability of COVID‐19 vaccine and its booster dose
por: Mubarak, Sawsan, et al.
Publicado: (2023)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
por: Zhou, Yan, et al.
Publicado: (2023)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
por: Qin, Xuzhen, et al.
Publicado: (2021)

Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia
por: Harapan, Harapan, et al.
Publicado: (2022)

COVID-19 Vaccine Booster Dose Acceptance among Older Adults
por: Sezerol, Mehmet Akif, et al.
Publicado: (2023)

Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis
por: Lahey, Timothy, et al.
Publicado: (2016)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jsdh0846c065qtlrngbcc4vla6